Evidence map›Paper›PMID 37612090›Full record

ArticleInternal medicine (Tokyo, Japan)2024

Lung Cancer Wherein Durvalumab Induced Both Anti-CRMP-5 Antibody-related Paraneoplastic Neurological Syndromes and Neurological Adverse Events.

Tomokazu Seki, Kousuke Baba, Tomohiro Hayashi, Risako Furuta, Hiroaki Hirosawa, Taichi Mitsui, Hiroki Maesaka, Syuhei Takasawa, Toshiro Miwa, Keiko Tanaka and 1 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Tomokazu SekiDepartment of Neurology, Faculty of Medicine, University of Toyama, Japan.
Kousuke BabaDepartment of Neurology, Faculty of Medicine, University of Toyama, Japan.
Tomohiro HayashiDepartment of Neurology, Faculty of Medicine, University of Toyama, Japan.
Risako FurutaDepartment of Neurology, Faculty of Medicine, University of Toyama, Japan.
Hiroaki HirosawaDepartment of Neurology, Faculty of Medicine, University of Toyama, Japan.
Taichi MitsuiDepartment of Neurology, Faculty of Medicine, University of Toyama, Japan.
Hiroki MaesakaDepartment of Neurology, Faculty of Medicine, University of Toyama, Japan.
Syuhei TakasawaDepartment of Neurology, Faculty of Medicine, University of Toyama, Japan.
Toshiro MiwaFirst Department of Internal Medicine, Toyama University Hospital, Japan.
Keiko TanakaDepartment of Animal Model Development, Bioresource Science Branch, Center for Bioresource-based Research, Brain Research Institute, Niigata University, Japan.
Yuji NakatsujiDepartment of Neurology, Faculty of Medicine, University of Toyama, Japan.
University of Toyama · JPNiigata University · JPToyama University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 68-year-old man with small-cell lung cancer developed anti-collapsin response-mediator protein (CRMP)-5 antibody-related paraneoplastic neurological syndrome (PNS) presenting with ataxia and chorea during treatment with durvalumab. As a result of steroid therapy, anti-CRMP-5 antibodies became negative, hyperintense lesions on brain magnetic resonance imaging disappeared, and neurological symptoms improved. After resuming durvalumab, he became unable to walk due to neurological adverse events (nAEs). There have been no reported cases manifesting PNSs and nAEs as a result of the same immune checkpoint inhibitors (ICIs) administered at different times. Resuming ICIs in patients diagnosed with PNSs should be performed with prudence.

Indexed as

Lung NeoplasmsParaneoplastic SyndromesSmall Cell Lung CarcinomaAgedAntibodies, MonoclonalHumansMaleAntibodies, Monoclonaldurvalumabanti-CRMP-5 antibodydurvalumabimmune checkpoint inhibitorsimmune-related adverse eventsneurological adverse eventsparaneoplastic neurological syndromes

Identifiers

PMID37612090
PMCPMC11045384
OpenAlexW4386058635

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.